Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2002 Oct 21;87(9):933-7.
doi: 10.1038/sj.bjc.6600591.

Oral cancer treatment: developments in chemotherapy and beyond

V J O'Neill  1 , C J Twelves
Affiliations
Review

Oral cancer treatment: developments in chemotherapy and beyond

V J O'Neill et al. Br J Cancer. .

Abstract

Oncology is one of the few areas of medicine where most patients are treated intravenously rather than receiving oral drugs. Recently, several oral anti-cancer drugs have been approved and there are many more in development. Oral chemotherapy is attractive because of its convenience and ease of administration, particularly in the palliative setting. With an increasing number of oral agents emerging, we can expect to see a rapid rise in the use of oral chemotherapy in years to come. This article reviews recent developments in oral chemotherapy, both of traditional cytotoxics and novel, targeted agents, from the viewpoint of patients, physicians, drug developers and health-care providers.

PubMed Disclaimer

References

    1. BornerMMDietrichDStuppRMorantRHoneggerHWernliMHerrmannRPestalozziBCSalettiPHanselmannSMullerSBrauchliPCastiglione-GertschMGoldhirschARothAD2002Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer J Clin Oncol 20717591766 - PubMed
    1. BaselgaJ2001The EGFR as a target for anticancer therapy–focus on cetuximab Eur J Cancer 37Suppl 4S16S22 - PubMed
    1. BaselgaJHerbstRLoRussoPRischinDRansonMPlummerRRaymondEMaddoxA-MKayeSBKieback DGHarrisAOchsJ2000Continuous Administration of ZD1839 (Iressa), a Novel Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), in Patients with Five Selected Tumor Types: Evidence of Activity and Good Tolerability Proc Am Soc Clin Oncol 19177
    1. CassidyJTwelvesCCameronDStewardWO'ByrneKJodrellDBankenLGogginTJonesDRoosBBushEWeidekammEReignerB1999Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients Cancer Chemother Pharmacol 446453460 - PubMed
    1. DeMarioMDRatainMJ1998Oral chemotherapy: rationale and future directions J Clin Oncol 16725572567 - PubMed

Substances